Join us at the 3rd annual Microbiome Movement Drug Development in Paris, France!
Lonza Pharma & Biotech continues to invest in drug delivery technologies and formulation services for microbiome applications, and will have a podium position at the Microbiome Movement.
Dr. Aurelien Sivert, Head of Pharmaceutical Product Applications Lonza, will be presenting the topic “Pioneering the Microbiome Oral Delivery for First-in-Man Studies” on the first full day of the conference (Jan 29). Lonza’s specialized encapsulation technologies, e.g. its intrinsically enteric capsule technologies, are being increasingly utilized in microbiome applications.
Intrinsically enteric capsule technologies represent a significant breakthrough in providing enteric protection and targeted delivery. By manufacturing two-piece hard shell capsules with pharmaceutical grades of enteric derivatives, full enteric protection can be achieved without the use of functional coatings. And by avoiding the high temperatures associated with coating processes, these technologies can enable the oral delivery of sensitive molecules such as live biotherapeutic products (LBP). These specialized encapsulation tools can also simplify and accelerate prototype development and rapid in-vivo testing of LBP’s and other products requiring enteric protection and targeted release within the GI tract.
Pioneering the Microbiome Oral Delivery for First-in-Man Studies
Tuesday 29 January 2019 at 17.50
Presented by: Aurelien Sivert, Head of Pharmaceutical Product Applications, Lonza